Use of lac activator proteins for regulated expression of oncogenes.
Labow
M A
MA
Roche Research Center, Hoffmann-La Roche Incorporated, Nutley, New Jersey 07110, USA.
D016475:3T3 Cells; D000199:Actins / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D015500:Chloramphenicol O-Acetyltransferase / Q000032:analysis / Q000096:biosynthesis; D003001:Cloning, Molecular / Q000379:methods; D005786:Gene Expression Regulation; D016158:Genes, p53; D005822:Genetic Vectors; D006367:HeLa Cells; D006801:Humans; D007544:Isopropyl Thiogalactoside / Q000494:pharmacology; D007739:L Cells; D051379:Mice; D009857:Oncogenes; D011401:Promoter Regions, Genetic; D051381:Rats; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000378:metabolism; D012097:Repressor Proteins / Q000187:drug effects / Q000378:metabolism*; D015534:Trans-Activators / Q000096:biosynthesis / Q000378:metabolism*; D014162:Transfection / Q000379:methods
D000199:Actins; D011994:Recombinant Proteins; D012097:Repressor Proteins; D015534:Trans-Activators; D007544:Isopropyl Thiogalactoside; D015500:Chloramphenicol O-Acetyltransferase